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Abstract
Erectile dysfunction (ED), defined by the Impotence-NIH Consensus Conference as the "persistent 
inability to achieve and/or maintain erection sufficient for satisfactory sexual activity" affect more than 
100 million men worldwide, at particular severity levels. The global prevalence of ED is estimated to 
affect about 10%, but has been found to increase significantly with age (39% in men 40 years of age and 
67% at 70 years of age). In men aged 40 to 70 years, the severe ED prevalence increased of three folds, 
5 to 15%. In order to evaluate the efficacy and tolerance of sildenafil, it was conducted a national open, 
multicentre study on a portuguese population affected by ED. Subjects under ambulatory treatment were 
recruited in Psychiatry/Sexology Clinical units and Urology/Andrology. The results of the study carried 
out on a group of 62 men with ED, demonstrate that sildenafil was effective in the recovering of erectile 
function, increasing the number of attempts to sexual activity and improving their success rates (mainly 
in severe dysfunction). Fifty one patients treated with sildenafil, at the end of the study referred a global 
improvement in their erections (92.2%). Doses of 50 mg and 100 mg sildenafil were used and were well 
tolerated and also effective in the treatment of this pathology (70% and 69% respectively). Being this 
study a flexible dose one and taking into consideration that the final dose used was found the more 
suitable to the patients, can be concluded that 43.1% of the patients elected dose of 50 mg whereas 
56.9% elected the maximum prescribed dose of 100 mg. Over and above global efficacy experimented 
by patients, a significant improvement in the sexual activity with partners was occurred. These results 
make possible a final conclusion--in the studied patients group affected by Erectile Dysfunction, aside 
from associated somatic pathology, sildenafil use provided a remarkable clinical profit, in what concerns 
global efficacy, by erectile function mechanisms improvement, concerning patients sensitivity of 
improvement, occurring in the major part of them, being these of high importance to the lifting up of 
their self-esteem.
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